ReviewWorld journal of microbiology & biotechnology2026
Development of Bacillus subtilis cell factories for nutraceuticals production.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nutraceuticals are products that contribute to health maintenance or physiological regulation. With the continuous growth in market demand, increasing attention has been paid to their production methods. Chemical synthesis and extraction from plants or animals generally suffer from complex processes, high costs, low yields, raw material shortages, and environmental pollution. In contrast, microbial synthesis is emerging as a promising alternative route for nutraceutical production. Among various microbial hosts, Bacillus subtilis has become an often-considered ideal chassis cell for the biosynthesis of nutraceuticals due to its GRAS status, well-characterized genetic background, and mature genetic manipulation platforms. This review systematically summarizes the synthetic biology tools and advanced metabolic engineering strategies employed in the construction of B. subtilis cell factories, critically compares their limitations, and highlights their applications in the biosynthesis of nutraceuticals. Furthermore, current challenges and future research directions are discussed. In summary, B. subtilis is expected to play an increasingly critical role in the efficient and sustainable biosynthesis of nutraceuticals.
Indexed as
Identifiers
42250015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.